Given the unclear role of CD73 in CCM, our team first studied its physiological role in CCM by myocardial-specific overexpression of CD73, and the source issue will also be a focus in our further study, which will provide a basis for precise treatment with CD73 as a therapeutic target. This evidence concerns the gene NT5E and cerebral cavernous malformation.